Eisai Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
With the impact of pandemic-prompted disturbances waning, analysts forecast better Q2 numbers for Indian pharma firms, with some including Glenmark and Cipla seen emerging winners. But after doing well in the quarter, Gilead’s licensees might see remdesivir demand tapering somewhat in Q3 post the WHO finding the antiviral ineffective in COVID-19 treatment.
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
Diagnosing and mapping COVID-19 are the keys to controlling the pandemic, and the IVDs industry is crucial to their success. But unclear messaging from the center is not helping, says incoming BIVDA chief operating officer Helen Dent.
- Other Names / Subsidiaries
- EA Pharma Co., Ltd.
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.